Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies

被引:63
|
作者
Xuan, Li [1 ]
Huang, Fen [1 ]
Fan, Zhiping [1 ]
Zhou, Hongsheng [1 ]
Zhang, Xian [1 ]
Yu, Guopan [1 ]
Zhang, Yu [1 ]
Liu, Can [1 ]
Sun, Jing [1 ]
Liu, Qifa [1 ]
机构
[1] So Med Univ, Nanfang Hosp, Dept Hematol, Guangzhou 510515, Guangdong, Peoples R China
来源
基金
中国国家自然科学基金; 高等学校博士学科点专项科研基金;
关键词
Epstein-Barr virus; Cytomegalovirus; Conditioning; Hematological malignancies; Allogeneic hematopoietic stem cell transplantation; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; ACUTE MYELOID-LEUKEMIA; BONE-MARROW-TRANSPLANTATION; POLYMERASE-CHAIN-REACTION; VERSUS-HOST-DISEASE; HIGH-RISK PATIENTS; IMMUNE RECONSTITUTION; REGIMENS; CHEMOTHERAPY; STRATEGIES;
D O I
10.1186/1756-8722-5-46
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Intensified conditioning regimens (increasing the intensity of standard myeloablative conditioning) for hematological malignancies in allogeneic hematopoietic stem cell transplantation (allo-HSCT) could reduce the relapse rate of the underlying disease, but it might simultaneously increase the transplant-related mortality including the mortality of infections. To explore whether intensified conditioning affected Epstein-Barr virus (EBV) and cytomegalovirus (CMV) infections, 185 patients undergoing allo-HSCT were enrolled. Methods: A total of 104 cases received standard and 81 intensified conditioning. Cyclosporine A (CsA) withdrawal and/or donor lymphocyte infusion (DLI) were conducted in high-risk patients. The EBV-DNA and CMV-DNA levels of blood were monitored regularly by quantitative real-time polymerase chain reaction (RQ-PCR) and immune reconstitution of recipients were analyzed by flow cytometry. Results: The 3-year cumulative incidence of EBV viremia, EBV-associated diseases and mortality of EBV-associated diseases were 25.3%+/- 4.6%, 10.5%+/- 3.4% and 0.0%+/- 0.0% in the standard group, compared with 45.6%+/- 6.5%, 26.0%+/- 5.3% and 7.3%+/- 3.1% in the intensified group (P=0.002, P=0.002, P=0.008). The 3-year cumulative incidence of CMV viremia and CMV-associated diseases, mortality of CMV-associated diseases and incidence of bacterial and fungal infections were similar between the two groups (P=0.855, P=0.581, P=0.933, P=0.142, P=0.182, respectively). Multivariate analysis showed that intensified conditioning was one of the risk factors for EBV viremia and EBV-associated diseases (P=0.037, P=0.037), but it had no effects on CMV infections. The percentage of CD4(+) T cells and CD4(+)/CD8(+) ratio at 3 months post-transplantation were lower in the intensified group (P=0.032, P=0.022). The 3-year OS and DFS in the standard group were 62.2%+/- 5.8% and 60.6%+/- 5.6%, compared with 51.6%+/- 6.2% and 51.1% +/- 5.9% in the intensified group (P=0.029, P=0.063). Conclusions: Intensified conditioning represents a promising approach for high-risk hematological malignancies, although it affects early immune reconstitution of recipients and increases the incidence and mortality of EBV infections.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Cytokine Gene Polymorphisms and Epstein-Barr Virus Infection after Allogeneic Hematopoietic Stem Cell Transplantation
    Lin, Ren
    Fan, Zhiping
    Zhao, Ke
    Jiang, Qianli
    Sun, Jing
    Liu, Qifa
    BLOOD, 2015, 126 (23)
  • [22] Epstein - Barr virus - associated Diseases in Allogeneic Hematopoietic Stem Cell Transplantation
    Xiu-li Wu
    Qi-fa Liu
    Journal of Hematology & Oncology, 5 (Suppl 1)
  • [23] Epstein-Barr virus infections after allogeneic stem cell transplantation: a comparison between non-malignant and malignant hematological disorders
    Islam, Md Serajul
    Anoop, Parameswaran
    Gordon-Smith, Edward C.
    Rice, Phil
    Datta-Nemdharry, Preeti
    Marsh, Judith C. W.
    HEMATOLOGY, 2010, 15 (05) : 344 - 350
  • [24] Incidence and Dynamics of Epstein-Barr Virus Reactivation After Alemtuzumab-Based Conditioning for Allogeneic Hematopoietic Stem-Cell Transplantation
    Carpenter, Ben
    Haque, Tanzina
    Dimopoulou, Maria
    Atkinson, Claire
    Roughton, Michael
    Grace, Sarah
    Denovan, Shari
    Fielding, Adele
    Kottaridis, Panagiotis D.
    Griffiths, Paul
    Mackinnon, Stephen
    Emery, Vincent
    Chakraverty, Ronjon
    TRANSPLANTATION, 2010, 90 (05) : 564 - 570
  • [25] Malignancies after heart transplantation:: presence of Epstein-Barr virus and cytomegalovirus
    Mattila, PS
    Aalto, SM
    Heikkilä, L
    Mattila, S
    Nieminen, M
    Auvinen, E
    Hedman, K
    Tarkkanen, J
    CLINICAL TRANSPLANTATION, 2001, 15 (05) : 337 - 342
  • [26] Adoptive T-cell Transfer for Refractory Viral Infections with Cytomegalovirus, Epstein-Barr Virus or Adenovirus after Allogeneic Stem Cell Transplantation
    Feucht, J.
    Joachim, L.
    Lang, P.
    Feuchtinger, T.
    KLINISCHE PADIATRIE, 2013, 225 (03): : 164 - 169
  • [27] Management of Epstein-Barr virus reactivation following allogeneic stem cell transplantation
    Lankester, Arjan C.
    REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, 2007, 12 (03) : 163 - 165
  • [28] Active cytomegalovirus infection is not a risk factor for Epstein-Barr virus DNAemia in the allogeneic stem cell transplantation setting
    Gimenez, Estela
    Solano, Carlos
    Bravo, Dayana
    Amat, Paula
    Jose Remigia, Maria
    Alberola, Juan
    Navarro, David
    CLINICAL TRANSPLANTATION, 2014, 28 (04) : 508 - 509
  • [29] A Co-Reactivation Model of Cytomegalovirus and Epstein-Barr Virus after Allogeneic Hematopoietic Stem Cell Transplantation Was Constructed to Predict Mortality after Transplantation
    Ren, Jinhua
    Chen, Shaozhen
    Hu, Jianda
    Yang, Ting
    BLOOD, 2023, 142
  • [30] Features of Epstein-Barr virus reactivation after reduced-intensity conditioning allogeneic stem cell transplantation
    Peric, Z.
    Chevallier, P.
    Guillaume, T.
    Delaunay, J.
    Ayari, S.
    Dubruille, V.
    Le Gouill, S.
    Mahe, B.
    Gastinne, T.
    Blin, N.
    Saulquin, B.
    Milpied, N.
    Vrhovac, R.
    Harousseau, J. L.
    Moreau, P.
    Coste-Burel, M.
    Imbert-Marcille, B. M.
    Mohty, M.
    BONE MARROW TRANSPLANTATION, 2010, 45 : S287 - S287